No DEPRINE indications
•No deprine is indicated to relief autonomic manifestations of anxiety such as:
1- Cardio-vascular manifestations: Tachycardia, palpitations, systolic hypertension and psychogenic cardiac pain (cardiac neurosis).
2- Gastro-intestinal manifestations: Difficulty in swallowing, heart burn, vomiting and diarrhea, abdominal distension, indigestion, constipation and anorexia.
3- Psychological and nervous manifestations: Headache, tremors, hyper-reflexia and hyper-activity, “pains allover” secondary to muscular spasm.
4- Sexual manifestations: Impotence, pre-mature ejaculation and frigidity.
5- Skin manifestations: Alopecia, vitiligo, rashes, urticaria, eczema, neurodermatitis, itching,.. etc.
6- Gynaecological manifestations: Dysmenorrhoea, premenstrual tension and climacteric syndrome.
7- Urinary manifestations: Frequency of micturition and incontinence.
8- Respiratory manifestations: Sighing, dyspnea, tightness in chest, hyperventilation that may lead to respiratory alkalosis resulting sometimes in tetany and numbness in the extremities.
•No deprine is indicated as adjuvant in “Psycho-somatic Disorders” such as:
Coronary artery disease, cardiac arrhythmias, hypertension, peptic ulcer, ulcerative colitis, IBS, bronchial asthma, …. etc.
No DEPRINE description
No DEPRINE (marketed under brand names Emandaxin and No DEPRINE) is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor and its psychopharmacological profile differs from such compounds. Although No DEPRINE is not approved for sale in North America, it is approved for use in various countries worldwide, including parts of Europe. The D-enantiomer (dextofisopam) is currently in phase II trials in the U.S. for the treatment of irritable bowel syndrome.
No DEPRINE dosage
Oral
Alcohol withdrawal syndrome; Short-term management of anxiety
Adult: 50-100 mg 1-3 times daily.
No DEPRINE side effects
Rare and include: Temporary gastrointestinal complaints, itching and exanthema. When exanthema appears, treatment should be discontinued. Usage in Pregnancy
Teratogenic effects have not been recorded so far, nevertheless, in the first three months of pregnancy, the use of No DEPRINE is not recommended.
No DEPRINE contraindications
Aggressive-impulsive psychopathy, 1st trimester of pregnancy.
Active ingredient matches for No DEPRINE:
Tofisopam in Egypt.
List of No DEPRINE substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Bydaxin (Japan) | |
| Clasopan (Japan) | |
| Cobandaxin (Japan) | |
| Emandaxin (Japan) | |
| Gesuben (Japan) | |
| Grandaxin (Bulgaria, Czech Republic, Egypt, Georgia, Hungary, Japan, Latvia, Lithuania, Romania, Russian Federation, Slovakia, Thailand, Vietnam) | |
| Tablet; Oral; Tofisopam 50 mg (Egis pharmaceuticals) | |
| Grandaxin 50 mg x 50 x 10's (Egis pharmaceuticals) | |
| Grandaxin 50 mg x 2 Blister x 10 Tablet (Egis pharmaceuticals) | |
| Grandaxin 10% (Japan) | |
| Grandaxin 50 mg (Hungary) | |
| Granpam (Japan) | |
| Hymidin (Japan) | |
| Isotan (South Korea) | |
| Myronin (Japan) | |
| Seriel (France) | |
| Tofiel (Japan) | |
| Tofilsin (Japan) | |
| Tofis (Japan) | |
| Tofisopam (Bulgaria, Czech Republic, Japan, South Korea, Vietnam) | |
| Tofisopam 10% (Japan) | |
| Tofisopam 10% CH (Japan) | |
| Tofisopam Choseido (Japan) | |
| Tofisopam Kyorin (Japan) | |
| Tofisopam Nichi-Iko (Japan) | |
| Tofisopam Ohara (Japan) | |
| Tolbanasin (Japan) | |
| Tronheim (Japan) | |
| Tsurubel (Japan) | |
References
- PubChem. "tofisopam". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "tofisopam". http://www.drugbank.ca/drugs/DB08811 (accessed September 17, 2018).
- MeSH. "Antidepressive Agents". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for No DEPRINE are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking No DEPRINE. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
1 consumer reported useful
Was the No DEPRINE drug useful in terms of decreasing the symptom or the disease?According to the reports released by ndrugs.com website users, the below mentioned percentages of users say the drug is useful / not useful to them in decreasing their symptoms/disease. The usefulness of the drug depends on many factors, like severity of the disease, perception of symptom, or disease by the patient, brand name used [matters only to a certain extent], other associated conditions of the patient. If the drug is not effective or useful in your case, you need to meet the doctor to get re-evaluated about your symptoms/disease, and he will prescribe an alternative drug.
| Users | % | ||
|---|---|---|---|
| Not useful | 1 | 100.0% | |
Consumer reported price estimates
No survey data has been collected yet2 consumers reported time for results
To what extent do I have to use No DEPRINE before I begin to see changes in my health conditions?As part of the reports released by ndrugs.com website users, it takes 1 day and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking No DEPRINE. To get the time effectiveness of using No DEPRINE drug by other patients, please click here.
| Users | % | ||
|---|---|---|---|
| 1 day | 1 | 50.0% | |
| > 3 month | 1 | 50.0% | |
7 consumers reported age
| Users | % | ||
|---|---|---|---|
| 30-45 | 3 | 42.9% | |
| 16-29 | 3 | 42.9% | |
| 46-60 | 1 | 14.3% | |
Consumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
